Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT04997733 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT04997733
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • Adults aged 18 to 74 years old
  • People who have been diagnosed with Crohn's disease (using a specific set of medical guidelines called the Lennard-Jones criteria) for at least 6 months
  • People whose Crohn's disease has been in remission (no active symptoms) for at least 6 months without using steroids, while on an anti-TNF medication, and who are willing to stop that anti-TNF treatment
  • Women of childbearing age who are using an active form of contraception throughout the treatment period (up to week 52 of the trial)
  • People who have health insurance coverage
  • People who have read, understood, and signed a written consent form agreeing to take part

For healthy volunteer donors:

  • Adults aged 18 to 49 years old
  • People with a body mass index (a measure of body weight relative to height) between 17 and 30
  • People who have regular bowel movements, meaning at least one bowel movement every two days but no more than two per day
  • People who have health insurance coverage
  • People who have read, understood, and signed a written consent form agreeing to take part

Who may not be able to join:

For patients:

  • People whose Crohn's disease has led to complications that require surgery
  • People for whom a colonoscopy (a camera examination of the bowel) or anaesthesia is not medically safe
  • People who are pregnant or breastfeeding during the study
  • People whose Crohn's disease only affects the upper digestive tract (such as the oesophagus, stomach, or upper small intestine)
  • People who currently have active disease around the anal or perineal area, such as an abscess, an open draining fistula, a surgical drain (seton), or an ulcer in that area
  • People who have had more than one surgery to remove part of the small bowel, or who have had more than one metre of small bowel removed
  • People who currently have or recently had a stoma (a surgically created opening in the abdomen for waste), or who have had any abdominal surgery in the 3 months before joining the trial
  • People currently taking part in another interventional research study
  • People who are under legal protection or guardianship

For healthy volunteer donors:

  • Full details are listed in the trial protocol — the trial site should be contacted directly for this information

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Harry SOKOL, PU-PH, Assistance Publique - Hôpitaux de Paris

Phone: 01 49 28 31 62

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
22 September 2021
Est. completion
22 May 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Evaluate the clinical efficacy of FMT versus sham transplantation as a maintenance treatment following anti-TNF agent withdrawal in patients with Crohn's disease in steroid-free clinical remission for at least 6 months under anti-TNF agent

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov